Compare SKIL & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKIL | ASRT |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.5M | 75.1M |
| IPO Year | N/A | 1997 |
| Metric | SKIL | ASRT |
|---|---|---|
| Price | $9.70 | $12.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 242.9K | 51.4K |
| Earning Date | 12-10-2025 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $515,774,000.00 | $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $4.65 | $7.71 |
| 52 Week High | $34.36 | $15.15 |
| Indicator | SKIL | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 79.07 |
| Support Level | $8.71 | $11.35 |
| Resistance Level | $9.82 | $12.54 |
| Average True Range (ATR) | 0.87 | 0.76 |
| MACD | 0.06 | -0.23 |
| Stochastic Oscillator | 64.30 | 86.92 |
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.